Pediatric Eustachian Tube Dilatation in the Management of Mesotympanic Retraction With Effusion. (PED-MR)

November 16, 2026 updated by: University Hospital, Montpellier

Pediatric Eustachian Tube Dilatation in the Management of Mesotympanic Retraction With Effusion: a Multicenter Randomized Study Versus Standard Treatment.

The goal of this clinical investigation is to evaluate the effectiveness of ETD + standard treatment versus standard treatment only, on the improvement of the tympanic membrane retraction, up to 18 months after intervention in children aged ]8-17[ with posterior mesotympanic retraction and middle ear effusion.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

272

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • APHM
      • Marseille, APHM, France, 13005
    • APHP Hôpital Necker
      • Paris, APHP Hôpital Necker, France, 75006
        • François SIMON
        • Contact:
    • APHP Hôpital Robert Debre
      • Paris, APHP Hôpital Robert Debre, France, 75019
        • Thiery VAN DEN ABBEELE
        • Contact:
        • Sub-Investigator:
          • Natacha TEISSIER, PhD
        • Sub-Investigator:
          • Charlotte BENOIT, Dr
        • Sub-Investigator:
          • Emilie BOIS, Dr
    • HCL Hôptial Femme Mere Enfant
      • Lyon, HCL Hôptial Femme Mere Enfant, France, 69677
        • Sonia AYARI
        • Contact:
        • Sub-Investigator:
          • Aurélie COUDERT, Dr
        • Sub-Investigator:
          • Maxime TABEY, Dr
    • Hôpital Purpan
      • Toulouse, Hôpital Purpan, France, 40031
        • Marie-Noël CALMELS
        • Contact:
        • Sub-Investigator:
          • Blandine BALADI
        • Sub-Investigator:
          • Yohan GALLOIS
    • Hôpital Salengro
      • Lille, Hôpital Salengro, France, 5900
        • Philippine TOULEMONDE
        • Contact:
        • Sub-Investigator:
          • Hugo DELERRY
        • Sub-Investigator:
          • Christophe VINCENT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children aged strictly between 8 and 17 years of age
  • Presenting a posterior mesotympanic retraction (grade II or III without adherence to the promontory from Sade's grade) with effusion

Exclusion Criteria:

  • Weight strictly less than 20kg
  • Down syndrome
  • Craniosynostosis and other head and neck malformations
  • History of skull base surgery
  • History of skull fracture
  • Failure to obtain consent
  • Non-affiliation to a social security scheme
  • Persons placed under legal protection
  • Person participating in another research including a period of exclusion still in progress

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Eustachian tube dilation added to standard treatment

Standard treatment involves the placement of a tympanostomy tube and adenoidectomy if a hypertrophy of the adenoids is present. ETD involves using a transnasal balloon catheter, during general anesthesia, by the surgeon in charge of the patient. The device will be an Acclarent Aera 6x16 mm balloon, with a pressure set at 12 atm for 2 minutes in the eustachian tube. The manufacturer of the ETD device will organize a training session with hands-on on simulator, for all the principal investigators prior to the start of the study, to ensure homogenous intervention.

Shepard tympanostomy tube, reference PRO 000 310P, manufactured by Pouret Medical, coupled with the Acclarent Aera™ Eustachian Tube Balloon Dilation System.

Active Comparator: Standard treatment

Standard treatment involves the placement of a tympanostomy tube and adenoidectomy if a hypertrophy of the adenoids is present, during general anesthesia, by the surgeon in charge of the patient. Tube placement will be in the anterior or inferior part of the tympanic membrane. Different design and brand of tympanostomy tube exist and are used in the different centers, leading to putative slightly different outcomes in term of adverse events related to the tympanostomy tube and duration. To decrease the cohort's heterogeneity, we propose to utilize the same tympanostomy tube for all the patients included in the study (Shepard's tympanostomy tube).

Medical device: Shepard tympanostomy tube, reference PRO 000 310P, manufactured by Pouret Medical.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tympanic membrane retraction
Time Frame: Tympanic membrane retraction will be assessed 3 times during the follow up: at 6, 12 and 18 months.

The assessment of tympanic membrane retraction is treated as a survival variable. Tympanic membrane retraction will be blindly assessed by an adjudication committee, through recorded otoendoscopy, based on the Sade's classification (in grade 0, I, II, III, IV, or V). The delay will be calculated as the time from intervention to improvement in tympanic membrane retraction (event), to loss of follow up (censoring), or to the study endpoint (censoring).

Tympanic membrane retraction will be assessed 3 times during the follow up: at 6, 12 and 18 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mesotympanic retractation
Time Frame: 6, 12 and 18 months

Mesotympanic retractation according to Sade's classification

6, 12 and 18 months
Audiometry thresholds
Time Frame: 6, 12 and 18 months

Mean of the air-bone gap at 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz

6, 12 and 18 months
Tympanometry profile
Time Frame: 6, 12 and 18 months

Tympanometry profile (A, B or C)

6, 12 and 18 months
The quality of life
Time Frame: 6, 12 and 18 months

Quality of Life measured through the OM-6 questionnaires

6, 12 and 18 months
The quality of life
Time Frame: 6, 12 and 18 months

Quality of Life measured through the PedsQL™ 4.0 questionnaires

6, 12 and 18 months
Adverse events in both arms
Time Frame: during the first week

Occurrence of adverse events and serious events during the first week, coded according to MedDRA.

during the first week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Fabian BLANC, Dr, University Hospital, Montpellier

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2027

Primary Completion (Estimated)

June 1, 2030

Study Completion (Estimated)

December 1, 2032

Study Registration Dates

First Submitted

November 16, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • RECHMPL26_0029
  • 2026-A01144-47 (Other Identifier: ID-RCB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.